Abstract: Oxidative stress is one of the risk factors for the development of several chronic diseases, such as diabetes, cancer, cardiovascular and neurodegenerative diseases. Antioxidants are therefore highly sought and can be seen as a type of preventive medicine against several diseases. *Myrica* and *Morella* genus (Myricaceae) are taxonomically very close and their species are trees or shrubs with edible fruits that exhibit relevant uses in traditional medicine, for instance in Chinese or Japanese folk medicine they are used to treat diarrhea, digestive problems, headache, burns and skin diseases. Nearly 36 compounds were isolated from different morphological parts of *Myrica* and/or *Morella* species and their antioxidant and anti-inflammatory activities evaluated. Thirteen of these compounds exhibit greater effects than the positive controls used. Adenodimererin A was the most active compound reported (in a 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay EC$_{50}$ = 7.9 ± 0.3 µM). These results are just one aspect of the antioxidant and anti-inflammatory evaluations reported regarding *Myrica* and *Morella* species, so a comprehensive overview on the current status, highlighting the antioxidant health promoting effect of these species, their key antioxidant compounds as
well as the compounds with protective effects against oxidative stress related diseases such as inflammation, is relevant.

**Keywords:** Morella; Myrica; antioxidant; anti-inflammatory; flavonoids; diarylheptanoid

### 1. Introduction

Pro-oxidants can be of endogenous or exogenous origin and lead to oxidative stress by creating reactive oxygen species (ROS) such as superoxide radical anion (O$_2^•$−), hydroxyl radical (OH•), peroxyl radical (ROO•) and hydrogen peroxide (H$_2$O$_2$), and/or reactive nitrogen species (RNS) such as nitric oxide radical (NO•) and peroxynitrite (ONOO−) [1,2]. ROS and RNS oxidize or nitrosylate proteins, unsaturated lipids, micronutrients and DNA (deoxyribonucleic acid) [3]. When at low levels, ROS and RNS have important physiological functions, such as in disulphide bond formation [4] and in a myriad of cellular signalling pathways [4,5]. For example, a recent review emphasizes the importance of these species in redox signalling pathways that mediate the immune response [6]. However, pathological oxidative stress arises when their concentrations exceed the maximum output of the cellular antioxidant enzyme systems (CAT (catalase), GPx (glutathione peroxidase), GR (glutathione reductase), Trx (thioredoxin), TR (thioredoxin reductase) and SOD (superoxide dismutase)), and other systems like small antioxidant molecules and apoptotic/repair mechanisms [4,7]. Due to the unspecific targets of ROS and RNS, it is unsurprising that a high levels of oxidative stress has been associated with increased risk for developing several chronic diseases in humans, such as chronic inflammatory response [8,9] cardiovascular [10,11], autoimmune and neurodegenerative diseases [12,13], cancer [9] and diabetes [14]. It is also responsible for faster aging due to telomere shortening [15], male infertility [16] and disuse muscle atrophy [17].

Antioxidants reduce oxidative stress and therefore play an essential role in improving well-being, preventing many of the pathological conditions listed above [7,14,16,18,19]. Antioxidant activity is usually related to direct scavenging of ROS and RNS. But it can also be related to inhibition of the enzymes that produce ROS and RNS, or the inhibition of NF-kB (nuclear factor kappa β) and the stimulation of Nrf-2 (nuclear factor erythroid 2-related factor 2, a regulator of cellular resistance to oxidants) [20]. Antioxidants can be used as functional foods, as dietary supplements, in complementary medicine systems and as additives in foodstuffs to maintain flavour [21,22]. Although they are generally harmless and have a massive importance in disease prevention, recent studies demonstrated that they can release acrylamide, a neurotoxin and carcinogen [23]. So care should be taken with their use because they can also be harmful [24].

In recent years secondary metabolites isolated and/or obtained by synthesis are considered more reliable [25] so the search for antioxidant secondary metabolites is a hot topic in the natural products research field. In this context, we will present the most recent developments on natural antioxidants isolated from Myrica and Morella species.
2. **Myrica and Morella Genera**

The *Myrica* genus belongs to the Myricaceae family and, before 2002 comprised about 97 species widely distributed by both temperate and sub-tropical regions [26,27]. Macdonald *et al.* [28] stated reasons for dismembering this genus in two, *Myrica* and *Morella*, but only in 2002 his arguments were accepted and the genus was split [29]. To clarify the distinction a taxonomic key was published in 2005 [30]. Thus, many of the species previously belonging to the *Myrica* genus have been reclassified and are now in the *Morella* genus. This taxonomic reclassification has several consequences in the natural products research field. Several studies published before 2005 report the isolation of secondary metabolites from the *Myrica* species, which are now *Morella* species, and this can cause misleading reports on secondary metabolites found for the first time in the genus. But it can also result in more recent publications that still use the previous scientific name, and consequently not be detected properly in a literature survey. Thus, we decided in this work, to join both genera and report their secondary metabolites to which antioxidant activities were endorsed.

*Morella* is by far the largest genus, having about 50 described species with a wide distribution in North America, Europe, Africa, and Asia [30]. All *Myrica* and *Morella* species are woody shrubs or tree pioneers in nitrogen-poor soils such as sandy soil or gravelly sites, because they are actinorhiza plants, and exhibit the ability to fix nitrogen through nitrogen-fixing root nodules induced by soil actinomycetes of the genus *Frankia*, with which it establishes a symbiotic relationship [31]. In addition to the economic interest of these species as source of paper and rope from the bark, as fuel wood, for biomass production and land reclamation, they are also appreciated because of their fruits that can be eaten raw, used in the production of jams, syrups and juices [27] and their applications in traditional medicine are also noteworthy. Indeed, several species of these genera are used as medicines in countries with relevant traditional medicine systems (see Table 1). Moreover, very important to remember, traditional medicine is either the mainstay of health care delivery or serves as its complement in many countries and the demand for its services is currently increasing [32].

| Table 1. Ethnopharmacological uses and distribution of *Myrica* and *Morella* species. |
|---------------------------------------------------------------|
| **Species Name** a | **Distribution** | **Traditional Uses** |
| *Morella adenophora* (Hance) J. Herb. | China and Taiwan | Roots and bark to treat bleeding, diarrhea and stomach pain [33]. |
| *Morella nana* (A. Chev.) J. Herb. | China | Fruits are beneficial for dyspepsia [34]. Roots are used to treat bleeding, diarrhea, stomach pain, burns, and skin diseases [35]. Bark is used to treat enteritis [36]. |
| *Morella serrata* (Lam.) Killick | South Africa and Southern African countries extending into tropical Africa | Used to treat asthma, coughing and shortness of breath [37]. The decoction of the root is used to treat painful menstruation, cold, coughs and headaches and to enhance male sexual performance [38]. It is also used in the management of sugar related disorder and as laxative to treat constipation. The stem bark is used to treat headache [39]. |
| *Morella arborea* (Hutch.) Cheek | Cameroon | Bark decoction used to treat fevers and inflammation [40]. |
Table 1. Cont.

| Species Name a | Distribution | Traditional Uses |
|----------------|--------------|------------------|
| *Morella cerifera* (L.) Small | North America | Herb decoction or tincture used as an astringent, diaphoretic, as a circulatory stimulant, to treat irritable bowel syndrome, ulcerative colitis, digestive system disorders, diarrhea, dysentery, leukorrhea, mucous colitis, colds, stomatitis, sore throat, measles and scarlet fever, convulsions, nasal catarrh and jaundice [41]. |
| *Morella salicifolia* (Hochst. ex A.Rich.) Verdc. & Polhill | Southeast Africa, Ethiopia and Saudi Arabia | Roots infusion is used to treat gastro-intestinal disorder [42] while roots and bark used in the treatment of headache [43], pain, inflammation and respiratory diseases [44]. |
| *Myrica rubra* (Lour.) Siebold & Zucc. | China, Japan, Taiwan and Korea | The various organs are used to treat gastrointestinal diseases, headaches, burns and skin diseases. Leaves are used to treat inflammatory diseases [45]. |
| *Myrica esculenta* Buch.-Ham. ex D. Don | India, South China, Malaya Islands, Pakistan and Nepal | Ayurvedic medicine use decoction of bark to treat asthma, bronchitis, fever, lung infection, dysentery, toothache and wounds [46–48]; leaf, root, bark and fruits juice for worms, jaundice and dysentery [48]; Vietnamese folk medicine uses bark to treat catarrhal fever, cough, sore throat and skin disease [49]. |
| *Myrica gale* L. | Europe, Siberia, Canada and Northern USA | Used in the treatment of ulcers, intestinal worms, cardiac disorders and aching muscles [50]. |
| *Myrica nagi* Thunb. | China, Malaya Islands, Pakistan and Nepal | Bark finds its application in reducing inflammations [51] to treat cardiac diseases, bronchitis, gonorrhea, diuresis, dysentery, epilepsy, gargoyle, haemoptysis, and paralysis and wounds [51,52]. Fruit wax or oil is used for treating ulcers [53], bleeding piles, body ache, toothache and for regulating the menstrual cycle [52]. |

a, Accepted name as indicated by The International Plant Names Index (IPNI) database.

Several of the traditional applications presented in Table 1, like the use of the oil from the flowers of *Myrica* species to treat inflammation, ear-ache and paralysis [27], are related to their potential to act on numerous oxidative stress effects being an important source of antioxidant and anti-inflammatory medicines. This potential unleashed the necessary and almost obligatory research to try to prove the beneficial effects suggested by traditional medicine as well as to look for the active ingredients responsible for the activities displayed. Herein are reviewed the most significant studies on the antioxidant and anti-inflammatory compounds isolated from species of the *Morella* and *Myrica* genera.

3. Isolated Compounds from *Morella*/*Myrica* Species

A revision of the literature published in the last 15 years, showed 116 compounds isolated from *Myrica*/*Morella* species, mostly cyclic diarylheptanoids, flavonoids and pentacyclic triterpenoids. It bears mentioning that there was little cross-species phytochemical variability to the point where some authors suggest that some cyclic diarylheptanoids, specially, myricanone 1 and myricanol 10, and some pentacyclic triterpenoids should be used as *Myrica*/*Morella* genus chemotaxonomic markers [54], while unusual C-methylated dihydrochalcones and flavonoids may support the segregation of some *Myrica* species to a new genus [55].
Several new diarylheptanoids (e.g., in Table 2), which have a unique 1,7-diphenylheptane structure and are distributed in a few botanic genera [56], have been isolated over the years from the *Myrica* genus (e.g., *Myrica rubra* [45]). Diarylheptanoids are known for their remarkable anti-inflammatory, antioxidant, antitumor, estrogenic, leishmanicidal, melanogenesis, hepatoprotective and neuroprotective activities [56,57].

**Table 2.** Compounds isolated from *Myrica* and *Morella* species with antioxidant and anti-inflammatory activities.

| Compound Name (Number) | Chemical Structure | Current Species Name *, Part of Plant |
|------------------------|--------------------|--------------------------------------|
| **Diarylheptanoids** | | |
| Myricanone (1) | | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. arborea* (Hutch.) Cheek, twigs [54]; *Mo. nana* (A. Chev.) J. Herb, roots [34]; *Mo. cerifera* (L.) Small, bark [59], twigs [60]; *My. gale* L. (syn. *My. gale* var. *tormentosa* L.), branches [61]; *My. rubra* (Lour.) Siebold & Zucc., bark [62] |
| 5-Deoxymyricanone (2) | | *Mo. adenophora* (Hance) J. Herb., roots [58] |
| Myricananin C (3) | | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. nana* (A. Chev.) J. Herb., roots [63] |
| 12-Hydroxymyricanone (4) | | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. nana* (A. Chev.) J. Herb, roots [63]; *My. gale* L. (syn. *My. gale* var *tormentosa* L.), branches [61] |
| Porson b (5) | | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. nana* (A. Chev.) J. Herb, roots [34]; *My. gale* L. (syn. *My. gale* var *tormentosa* L.), branches [61] |
| Myricananin D (6) | | *Mo. adenophora* (Hance) J. Herb., [58]; *Mo. nana* (A. Chev.) J. Herb, roots [63] |
| Alnusonol (7) | | *Mo. nana* (A. Chev.) J. Herb, roots [63] |
| Actinidione (8) | | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. nana* (A. Chev.) J. Herb, roots [63] |
| Compound Name (Number) | Chemical Structure | Current Species Name *, Part of Plant |
|------------------------|-------------------|---------------------------------------|
| Galeon (9)             | ![Chemical Structure](image1) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *My. gale* L. (syn. *My. gale var tormentosa* L.), branches [64] |
| Myricanol (10)         | ![Chemical Structure](image2) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. arborea* (Hutch.) Cheek, root and stem barks [40], twigs [54]; *Mo. cerifera* (L.) Small, bark [59], root-bark [65]; *My. esculenta* Buch.-Ham. ex D.Don, leaves [66]; *Mo. nana* (A. Chev.) J. Herb, roots [34]; *My. rubra* (Lour.) Siebold & Zucc., bark [62] |
| Myricanol 11-O-β-D-xylopyranoside (11) | ![Chemical Structure](image3) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. arborea* (Hutch.) Cheek, root and stem barks [40] |
| Myricanol 11-O-β-D-glucopyranoside (12) | ![Chemical Structure](image4) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *Mo. nana* (A. Chev.) J. Herb, roots [35]; *My. rubra* (Lour.) Siebold & Zucc., bark [62] |
| Myricanol 5-O-β-D-glucopyranoside (13) | ![Chemical Structure](image5) | *My. rubra* (Lour.) Siebold & Zucc., bark [62] |
| Myricanol 5-O-β-D-(6′-O-galloyl)-glucopyranoside (14) | ![Chemical Structure](image6) | *My. rubra* (Lour.) Siebold & Zucc., bark [62] |
| Myricananin A (15)     | ![Chemical Structure](image7) | *Mo. nana* (A. Chev.) J. Herb, roots [63] |
| Juglanin B-11(R)-O-sulphate (16) | ![Chemical Structure](image8) | *My. rubra* (Lour.) Siebold & Zucc., leaves [67] |

**Flavonoids**

| Compound Name (Number) | Chemical Structure | Current Species Name *, Part of Plant |
|------------------------|-------------------|---------------------------------------|
| Myricetin 3-O-(2-O-galloyl)-α-L-rhamnopyranoside (17) | ![Chemical Structure](image9) | *My. rubra* (Lour.) Siebold & Zucc., leaves [68] |
| Myricetin 3-O-(2-O-galloyl)-β-D-galactopyranoside (18) | ![Chemical Structure](image10) | *My. rubra* (Lour.) Siebold & Zucc., leaves [68] |
| Compound Name (Number) | Chemical Structure | Current Species Name *, Part of Plant |
|------------------------|--------------------|----------------------------------------|
| Quercetin 3-O(2-O-galloyl)-β-D-galactopyranoside (19) | ![Chemical Structure](image) | *My. rubra* (Lour.) Siebold & Zucc., leaves [68] |
| Myricetin (20) | ![Chemical Structure](image) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *My. rubra* (Lour.) Siebold & Zucc., leaves [68], bark [62]; *Mo. cerifera* (L.) Small, root-bark [65]; *My. esculenta* Buch.- Ham. ex D.Don, leaves [66] |
| Myricetin-3′-O-sulfate (21) | ![Chemical Structure](image) | *My. rubra* (Lour.) Siebold & Zucc., leaves [67] |
| Ampelopsin 3′-O-sulfate (22) | ![Chemical Structure](image) | *My. rubra* (Lour.) Siebold & Zucc., leaves [67] |
| Myricitrin (23) | ![Chemical Structure](image) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *My. rubra* (Lour.) Siebold & Zucc., leaves [68], bark [62]; *Mo. cerifera* (L.) Small, root-bark [65]; *My. esculenta* Buch.- Ham. ex D.Don, leaves [66] |
| Quercitrin (24) | ![Chemical Structure](image) | *Mo. adenophora* (Hance) J. Herb., roots [58] |
| Adenodimerin A (25) | ![Chemical Structure](image) | *Mo. adenophora* (Hance) J. Herb., roots [58] |
| Myricitrin (23) | ![Chemical Structure](image) | *Mo. adenophora* (Hance) J. Herb., roots [58]; *My. rubra* (Lour.) Siebold & Zucc., leaves [68], bark [62]; *Mo. cerifera* (L.) Small, root-bark [65]; *My. esculenta* Buch.- Ham. ex D.Don, leaves [66] |
Table 2. Cont.

| Compound Name (Number) | Chemical Structure | Current Species Name a, Part of Plant |
|------------------------|-------------------|--------------------------------------|
| Procyanidin B2 (26)    | ![Image](image1)   | *My. rubra* (Lour.) Siebold & Zucc., fruit pulp [69] |
| (−)-Epicatechin (27)   | ![Image](image2)   | *My. rubra* (Lour.) Siebold & Zucc., fruit pulp [69]; *My. gale* L., aerial parts [70] |
| Cyanidin 3-O-glucopyranoside (28) | ![Image](image3) | *My. rubra* (Lour.) Siebold & Zucc., fruits [45] |
| **Miscellaneous Compounds** |                     |                                       |
| Myricalactone (29)     | ![Image](image4)   | *Mo. adenophora* (Hance) J. Herb., roots [58]; *My. gale* L. (syn. *My. gale* var *tormentosa* L.), stem [64] |
| 3β-Trans-p-coumaroyloxy-2α,23-dihydroxyolean-12-en-28-oic acid (30) | ![Image](image5) | *Mo. adenophora* (Hance) J. Herb., roots [58] |
| Rhoiptelenol (31)      | ![Image](image6)   | *My. rubra* (Lour.) Siebold&Zucc., bark [71] |
| Ursolic acid (32)      | ![Image](image7)   | *My. rubra* (Lour.) Siebold&Zucc., bark [71] |
| β-Sitosterol (33)      | ![Image](image8)   | *Mo. adenophora* (Hance) J. Herb., roots [58]; *My. esculenta* Buch.- Ham. ex D.Don, leaves [72] |
| 6′-O-galloyl orbicularin (34) | ![Image](image9) | *Mo. adenophora* (Hance) J. Herb., roots [58] |
Flavonoids are common plant secondary metabolites (e.g., in Table 2), well known for having several biological activities in vitro and in vivo among which we can highlight their remarkable antioxidant activity, leading to lower chronic disease development [74]. However, some are pro-oxidants as structures with more hydroxyl groups actually lead to an increase in ROS by the Fenton reaction rather than antioxidant activity [74]. Flavonoids also have interesting anti-inflammatory activities against several markers in vitro, but in vivo studies are still lacking [75].

Pentacyclic triterpenoids are widespread through the plant kingdom and oleanane-type structures are commonplace [76]. Morella and Myrica genera proved to be no exception. Several activities and molecular targets are associated with this compound type, including antioxidant and anti-inflammatory [77].

From the 116 compounds isolated from Myrica/Morella species, about a third were evaluated from the point of view of antioxidant and/or anti-inflammatory activities and from these, only 36 compounds were considered in Table 2. Our choice was based on their higher activity and/or on those that allowed structure/activity relationship establishments. And those results will be discussed in the following points of this review.

One important conclusion that arises from Table 2 analysis is that, although Myrica and Morella genera have several plants with edible fruits with medicinal applications (Table 1) most antioxidant and anti-inflammatory studies were done with secondary metabolites isolated from roots, bark and leaves (Table 2). Nevertheless, finding beneficial antioxidant effects in these species and assessing their usefulness as food supplements, additives or as coadjuvants in certain treatments which imply severe ROS/RNS imbalance, not only enhances market interest in their exploration, but also allows the customer to know the health-promoting effects that they might have.
4. Biological Activities

4.1. Antioxidant Activity

Antioxidant activity is considered a key mechanism to prevent many diseases [78–80], including inflammation, diabetes, cancer and cardiovascular diseases. In fact some antioxidants are considered important nutraceuticals due to their beneficial health effects.

Antioxidant activity assays are common and diverse; in recent remarks 407 variants of 29 different in vitro and in vivo methods for assaying antioxidant capacity were discussed [78]. These different approaches give rise to important issues involving the use of different positive controls, different reagent concentrations and reaction times [80]. Consequently comparisons are almost impossible and to disclose the quality of the reported results is very difficult.

In this work, we decided to highlight and discuss the results (Table 3) obtained by the most common in vivo and in vitro methods whose trials were performed according to good practice suggestions [80] and that were considered trustworthy (i.e., that exhibit statistical treatment and use a positive control) in order to show the antioxidant potential of several compounds isolated from Myrica and Morella species.

Not only we want to highlight the antioxidant potential of these secondary metabolites but also to discuss some weaknesses and/or strengths of the used methods, and in doing so we expect to stimulate our readers to be more careful and critical in their research methodologies.

Table 3. Antioxidant activity of the isolated compounds from Myrica and Morella species.

| Compound | Antioxidant Activity (Positive Control Used) |
|----------|---------------------------------------------|
| 1        | DPPH: EC$_{50}$ = 202.7 ± 15.8 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 19.6 ± 0.7 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 2        | DPPH: EC$_{50}$ ≥ 250 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 102.7 ± 12.4 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 3        | DPPH: EC$_{50}$ = 16.3 ± 2.8 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 12.0 ± 0.6 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 5        | DPPH: EC$_{50}$ > 250 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 73.7 ± 0.1 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 6        | DPPH: EC$_{50}$ = 87.8 ± 0.0 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | EC$_{50}$ = 14.9 µM (α-Tocopherol EC$_{50}$ = 27.1 µM) [62] |
|          | ABTS: EC$_{50}$ = 85.9 ± 2.7 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 8        | DPPH: EC$_{50}$ = 195.4 ± 2.2 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 89.1 ± 0.6 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 9        | DPPH: EC$_{50}$ = 51.1 ± 2.9 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 26.8 ± 1.6 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 10       | DPPH: EC$_{50}$ = 198.9 ± 9.1 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 22.3 ± 0.6 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 11       | DPPH: EC$_{50}$ = 81.6 ± 3.7 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | ABTS: EC$_{50}$ = 25.3 ± 2.6 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
| 12       | DPPH: EC$_{50}$ > 250 µM (Ascorbic acid EC$_{50}$ = 22.25 ± 0.4 µM) [58] |
|          | EC$_{50}$ = 12.9 µM (α-Tocopherol EC$_{50}$ = 27.1 µM) [62] |
|          | ABTS: EC$_{50}$ = 19.6 ± 0.2 µM (Ascorbic acid EC$_{50}$ = 23.3 ± 0.2 µM) [58] |
A glance at the results indicated in Table 3 shows that the most used positive control is ascorbic acid, a commercially available potent antioxidant with remarkable beneficial effects in human health [83] and the recommended standard for the DPPH antioxidant assay [80]. Another important assumption is that out of the 26 compounds assayed, 13 had higher activity than the tested positive controls being in some cases nearly three times more active than ascorbic acid. These interesting results can corroborate the plant traditional use.

Following the DPPH assay results, it can be disclosed that the most active compound (2.8-fold more active than ascorbic acid) is adenodimerin A (25), a new proanthocyanidin type A recently isolated from...
Morella adenophora roots [58]. Compound 14, a myricanol derivative, and compounds 20, 23 and 26, flavonoid derivatives, showed DPPH scavenging activity lower than 25 and also lower than α-tocopherol and BHA, other commercially available antioxidant references. However, the authors [62,69] did not present the associated errors and this lowers the credibility in their results. Regarding the error associated to EC\textsubscript{50} values, it is negatively surprising that, beyond the cases where it is not shown \cite{62,69}, several other results showed standard deviation higher than 5\% (compounds 1 and 9 in DPPH assay and compounds 9, 20 and 25 in ABTS assay) and even higher than 10\% (compound 3 in DPPH assay and compounds 2 and 11 in ABTS assay). Such high margins of error make the results unreliable and therefore diminish their scientific interest. Authors, reviewers and editors must be more and more attentive to this so that published works have the greatest rigor and impact.

We were confronted with another difficulty that result from the significantly fluctuating EC\textsubscript{50} values, as an example we can highlight the EC\textsubscript{50} results for compound 12 in two DPPH assays, moreover the authors \cite{58,62} used the same method, only the positive control is different, and this cannot explain the very high variation.

Table 3 analyses of the DPPH assay data also allowed interesting conclusions about diarylheptanoid antioxidant action: (a) diarylheptanoid derivatives are less active than flavonols, only compounds 3 and 14, exhibit EC\textsubscript{50} below 20 \mu M and are more active than ascorbic acid and α-tocopherol respectively; (b) a hydroxyl group at carbon C-11 instead of a carbonyl do not improve the activity (e.g., compounds 1 and 10); (c) an extra hydroxyl group at carbon C-5 is also irrelevant (e.g., compounds 1 and 2); (d) on the other hand the loss of a methyl group (e.g., compounds 2 and 3) causes a strong increase in antioxidant effect; (e) it seems that the presence of a sugar moiety, the type of sugar and its localization, also interfere with the antioxidant activity (e.g., compounds 10 to 14).

Nevertheless the results obtained with several flavonols in the NBT assays allowed some interesting conclusions: (a) the presence of an extra hydroxyl group at C-3′ increases the activity (e.g., compounds 18 and 19); (b) the presence of sugar derivative substituent at C-3 also increases the activity (e.g., compounds 17, 18, 20 and 23).

From our literature survey and resumed in Table 3 it is noteworthy that the antioxidant evaluation against the most common ROS species are unusual.

Although oleanane-type compounds are recognized as important scaffolds \cite{76} the derivatives found in Morella/Myrica genus were almost inactive in the antioxidant evaluations performed.

Our literature research herein presented and discussed revealed that in vivo antioxidant studies involving compounds isolated from Myrica/Morella genus were nor reported, naturally due to the difficulties inherent to the in vivo methodologies. However, the in vitro studies do not reflect the compound’s actual antioxidant activity. After their consumption, compounds can be metabolized and lose activity, but above all can generate unwanted metabolites that can be toxic. So greater effort from the scientific community to use in vivo methodologies as well as investigations of toxicity and side effects are highly recommended.

It can also be noted that other species of these genera should be studied and more attention to their fruits is also needed.

Recent works enhance the application of the Morella and Myrica species, as supplement and/or nutraceutical were not herein discussed because they are beyond the scope of this review; in fact they deal with extract mixtures and not with pure isolated compounds \cite{45,84,85}.
4.2. Anti-Inflammatory Activity

As referred at the beginning of this work, a high intracellular ROS level may activate various ROS-sensitive signaling pathways and promote inflammatory gene expression in a very large number of clinical situations involving very different symptomatology. In the inflammatory process there are several mediators, some of which have been used as the prime targets to find new anti-inflammatory agents. The most common are: (a) the pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, mediators of immune response that contribute for the activation and amplification of the inflammatory response pathway initiated with Th1 cells [86,87]; (b) nitric oxide, a mediator similar to neurotransmitters in the neuronal system, which can be produced by inducible nitric oxide synthase stimulated by cytokines and bacterial pathogens [88,89]; (c) PGE2 (prostaglandin E2), a known inflammatory mediator in chronic diseases, being a major compound in late/chronic inflammation and is also a common pharmaceutical target for both steroidal and non-steroidal anti-inflammatory drugs [90].

Compounds isolated from *Myrica* and *Morella* species were assayed for their anti-inflammatory activity and effect on some of the most common inflammatory markers, the most relevant data is gathered in Table 4. Again we excluded some results due to the fact that authors do not report IC$_{50}$ values and inhibition percentage do not provide reliable information.

**Table 4.** Anti-inflammatory activities of isolated compounds from *Myrica* and *Morella* species.

| Compound | Anti-Inflammatory Activity (Positive Control Used) | Reference |
|----------|---------------------------------------------------|-----------|
| 1        | IC$_{50}$ (iNOS) = 1.0 ± 0.1 µM (N$_ω$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM; Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM) | [58] |
| 3        | IC$_{50}$ (iNOS) = 13.0 ± 0.9 µM (N$_ω$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM; Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM) | [58] |
| 4        | IC$_{50}$ (NO) = 63.51 µM (N-monomethyl-L-arginine IC$_{50}$ = 64.24 µM) * | [63] |
| 5        | IC$_{50}$ (iNOS) = 46.9 ± 3.1 µM (N$_ω$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM; Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM) | [58] |
| 6        | IC$_{50}$ (NO) = 23 µM (N$_ω$-nitro-L-arginine IC$_{50}$ = 28 µM) | [71] |
| 7        | IC$_{50}$ (NO) = 46.18 µM (N-monomethyl-L-arginine IC$_{50}$ = 64.24 µM) | [63] |
| 10       | IC$_{50}$ (iNOS) = 7.5 ± 2.7 µM (N$_ω$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM; Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM) | [58] |
| 15       | IC$_{50}$ (NO) = 45.32 µM (N-monomethyl-L-arginine IC$_{50}$ = 64.24 µM) | [63] |
| 16       | IC$_{50}$ (TNF-α) = 20.1 ± 2.14 µM (PDTC IC$_{50}$ = 16.8 ± 2.13 µM; Quercetin IC$_{50}$ = 13.6 ± 0.81 µM); IC$_{50}$ (IL-1β) = 22.9 ± 0.75 µM (PDTC IC$_{50}$ = 18.0 ± 1.74 µM; Quercetin IC$_{50}$ = 16.9 ± 0.34 µM); IC$_{50}$ (IL-6) = 22.7 ± 1.61 µM (PDTC IC$_{50}$ = 16.8 ± 2.40 µM; Quercetin IC$_{50}$ = 16.8 ± 0.13 µM) | [67] |
Table 4. Cont.

| Compound | Anti-Inflammatory Activity (Positive Control Used) a | Reference |
|----------|-----------------------------------------------------|-----------|
| 17       | IC$_{50}$ (TNF-α) = 12.90 ± 0.84 µM (PDTC IC$_{50}$ = 25.32 ± 0.51 µM) | [68]      |
|          | IC$_{50}$ (IL-1β) = 18.06 ± 3.16 µM (PDTC IC$_{50}$ = 23.61 ± 2.17 µM) |           |
|          | IC$_{50}$ (IL-6) = 7.69 ± 2.14 µM (PDTC IC$_{50}$ = 21.41 ± 1.69 µM) |           |
| 18       | IC$_{50}$ (TNF-α) = 8.65 ± 1.62 µM (PDTC IC$_{50}$ = 25.32 ± 0.51 µM) | [68]      |
|          | IC$_{50}$ (IL-1β) = 18.97 ± 2.15 µM (PDTC IC$_{50}$ = 23.61 ± 2.17 µM) |           |
|          | IC$_{50}$ (IL-6) = 13.14 ± 0.44 µM (PDTC IC$_{50}$ = 21.41 ± 1.69 µM) |           |
| 19       | IC$_{50}$ (TNF-α) = 1.55 ± 1.15 µM (PDTC IC$_{50}$ = 25.32 ± 0.51 µM) | [68]      |
|          | IC$_{50}$ (IL-1β) = 17.84 ± 1.56 µM (PDTC IC$_{50}$ = 23.61 ± 2.17 µM) |           |
|          | IC$_{50}$ (IL-6) = 8.63 ± 2.14 µM (PDTC IC$_{50}$ = 21.41 ± 1.69 µM) |           |
| 20       | IC$_{50}$ (TNF-α) = 65.21 ± 3.11 µM (PDTC IC$_{50}$ = 25.32 ± 0.51 µM) | [68]      |
|          | IC$_{50}$ (IL-1β) = 22.81 ± 2.51 µM (PDTC IC$_{50}$ = 23.61 ± 2.17 µM) |           |
|          | IC$_{50}$ (IL-6) = 23.65 ± 6.14 µM (PDTC IC$_{50}$ = 21.41 ± 1.69 µM) | [71]      |
|          | IC$_{50}$ (NO) = 99 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 28 µM) |           |
| 21       | IC$_{50}$ (TNF-α) = 19.9 ± 2.45 µM (PDTC IC$_{50}$ = 16.8 ± 2.13 µM) | [67]      |
|          | Quercetin IC$_{50}$ = 13.6 ± 0.81 µM IC$_{50}$ (IL-1β) = 20.2 ± 1.42 µM |           |
|          | (PDTC IC$_{50}$ = 18.0 ± 1.74 µM; Quercetin IC$_{50}$ = 16.9 ± 0.34 µM) |           |
|          | IC$_{50}$ (IL-6) = 22.2 ± 1.14 µM (PDTC IC$_{50}$ = 16.8 ± 2.40 µM) |           |
|          | Quercetin IC$_{50}$ = 16.8 ± 0.13 µM) |           |
| 22       | IC$_{50}$ (TNF-α) = 20.1 ± 2.14 µM (PDTC IC$_{50}$ = 16.8 ± 2.13 µM) | [67]      |
|          | Quercetin IC$_{50}$ = 13.6 ± 0.81 µM IC$_{50}$ (IL-1β) = 22.9 ± 0.75 µM |           |
|          | (PDTC IC$_{50}$ = 18.0 ± 1.74 µM Quercetin IC$_{50}$ = 16.9 ± 0.34 µM) |           |
|          | IC$_{50}$ (IL-6) = 22.7 ± 1.61 µM (PDTC IC$_{50}$ = 16.8 ± 2.40 µM) |           |
|          | Quercetin IC$_{50}$ = 16.8 ± 0.13 µM) |           |
| 23       | IC$_{50}$ (iNOS) = 30.9 ± 2.1 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM) | [58]      |
|          | Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM |           |
| 24       | IC$_{50}$ (iNOS) = 45.4 ± 0.89 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM) | [58]      |
|          | Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM |           |
| 28       | IC$_{50}$ (NO) = 30.19 µM (N$\omega$-monomethyl-L-arginine IC$_{50}$ = 64.24 µM) | [63]      |
| 31       | IC$_{50}$ (NO) = 24 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 28 µM) | [71]      |
| 32       | IC$_{50}$ (NO) between 3–10 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 28 µM) | [71]      |
| 33       | IC$_{50}$ (iNOS) = 39.5 ± 2.7 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM) | [58]      |
|          | Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM |           |
| 35       | IC$_{50}$ (iNOS) = 18.1 ± 1.5 µM (N$\omega$-nitro-L-arginine IC$_{50}$ = 39.5 ± 2.7 µM) | [58]      |
|          | Aminoguanidine IC$_{50}$ = 22.2 ± 3.6 µM |           |

a, iNOS, Inducible nitric oxide synthase; TNF-α, Tumour necrosis factor α; IL, Interleucine; NO, nitric oxide production in lipopolysaccharide-stimulated RAW 264.7 cells; PDTC, Pyrrolidine dithiocarbamate; IC$_{50}$, Inhibitory concentration for half maximal enzyme activity.
The anti-inflammatory potential of *Myrica*/*Morella* species seems to be effective, since from the 43 assays whose results are shown in Table 4, 13 exhibited higher activities than the positive control tested which is quite remarkable. The diarylheptanoids myricanone 1 and myricanol 10, are very active iNOS inhibitors, since they are, respectively, 20 and four times more active than the most active control tested (aminoguanidine IC₅₀ = 22.2 µM), while the flavonols myricetin 3-O-(2-O-galloyl)-β-D-galactopyranoside 18 and quercetin 3-O-(2-O-galloyl)-β-D-galactopyranoside derivatives 19 are able to reduce significantly the release of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6).

Despite the high anti-inflammatory potential revealed by the results shown in Table 4, some of them have unusually high standard deviation values (>10% activity value) and their higher activity should be considered with caution. For instance we can indicate three particularly surprising cases, the inhibitory effect of compound 17 on IL-6 (7.69 ± 2.14 µM) [68], of compound 10 on iNOS (7.5 ± 2.7 µM) [58] and of compound 19 on TNF-α (1.55 ± 1.15 µM) [68], where errors are displayed from 28% to 74%. Also results without any statistical evaluation were reported [71]. This limits the impact of these results, and again indicates that results should always be evaluated critically.

In view of the structure/activity relationship, it is noteworthy that Kim *et al.* [67] also tested the inhibitory effect on TNF-α, IL-1β and IL-6 of the compounds 16, 21 and 22 aglycones, however their results did not reveal significant changes in the activity. These results are important to demonstrate that the 3′-O-sulfate group in a flavonoid structure can be used to improve the compound solubility in water, without affecting its anti-inflammatory action. As far as we are aware, these authors were also the only ones that simultaneously measured RAW 264.7 cell viability at a concentration greater than the IC₅₀ value. In fact, only with this methodology is it possible to conclude that anti-inflammatory effect is not due to cytotoxicity of the compounds tested.

The results also showed that compound 20 is less active to inhibit the TNF-α and IL-6 cytokines than its 3-O-rhamnoside derivative 23 and even less effective than derivatives 17 and 18. On the other hand, compound 19, whose structure differs from compound 18 only in an additional 3′-OH group, reduces the release of pro-inflammatory cytokines TNF-α and IL-6 more than any of the foregoing compounds. These facts suggest that: (a) the non-free 3-OH group is an important structural scaffold to show inhibitory activity on cytokines TNF-α and IL-6; (b) once more the presence of a galloyl group, seems to have a positive effect on the activity.

In Table 4 are included results where the compound tested is not more active than the positive control, meaning that the tested compounds are not good enough. But their activity can provide some scientific support for the traditional uses reported in Table 1.

Again we can conclude that more in depth studies are lacking, for instance toxicity evaluations and *in vivo* studies.

5. Conclusions

Secondary metabolites with unusual structures and exhibiting antioxidant and anti-inflammatory activities, high enough to capture the attention of researchers and to be considered as potential drug leads, were isolated from *Myrica*/*Morella* species; some of the traditional medicine uses of these species are adequately justified. It is nonetheless curious that, while the fruits of *Morella* and *Myrica* species
are edible, and therefore commercially quite valuable, most of the relevant studies on antioxidant and anti-inflammatory activities of the compounds tested were isolated from bark, leaves and roots.

Clearly, much has been done, but much remains to do. From the biological evaluation point of view: (a) toxicity testing is lacking; (b) more specifically in-depth studies on the mechanisms of action are needed; (c) \textit{in vivo} evaluations are necessary; (d) standardization of the methodologies; and (e) more compounds should be tested to elaborate the more detail structure-activity relationships. From the chemical point of view: (a) more species should be phytochemically analyzed; and (b) more detailed analysis in the compounds structure characterization is necessary, since for example some compounds are reported and tested without their stereogenic centers properly elucidated.

This review hopes to raise awareness and drive interest for further research on these genera with minds set on ensuring the quality of traditional uses and maybe turning them into pharmacological alternatives to the ones that already exist on the market.

Acknowledgments

Thanks are due to “Fundação para Ciência e Tecnologia”/“Ministério da Educação e Ciência” for the financial support to the “Química Orgânica Produtos Naturais e Agroalimentares” research Unit (FCT UID/QUI/00062/2013), through national founds and where applicable co-financed by the “Fundo Europeu de Desenvolvimento Regional”, within the PT2020 Partnership Agreement and to University of Azores.

Author Contributions

Diana C. G. A. Pinto and Ana M. L. Seca provided the initial ideas and stimulus for writing this review. Bruno J. C. Silva along with previous authors wrote the manuscript, while Maria do Carmo Barreto provided critical comment on the content of the review.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Apel, K.; Hirt, H. Reactive oxygen species: Metabolism, oxidative stress, and signal transduction. \textit{Annu. Rev. Plant Biol.} \textbf{2004}, \textit{55}, 373–399.
2. Phaniendra, A.; Jestadi, D.B.; Periyasamy, L. Free radicals: Properties, sources, targets, and their implication in various diseases. \textit{Ind. J. Clin. Biochem.} \textbf{2015}, \textit{30}, 11–26.
3. Newsholme, P.; Rebelato, E.; Abdulkader, F.; Krause, M.; Carpinelli, A.; Curi, R. Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: A critical role for amino acids. \textit{J. Endocrinol.} \textbf{2012}, \textit{214}, 11–20.
4. Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. \textit{Curr. Biol.} \textbf{2014}, \textit{24}, R453–R462.
5. Reczek, C.R.; Chandel, N.S. ROS-dependent signal transduction. \textit{Curr. Opin. Cell Biol.} \textbf{2015}, \textit{33}, 8–13.
6. Lei, Y.; Wang, K.; Deng, L.; Chen, Y.; Nice, E.C.; Huang, C. Redox regulation of inflammation: Old elements, a new story. *Med. Res. Rev.* **2015**, *16*, 306–340.

7. Rahal, A.; Kumar, A.; Singh, V.; Yadav, B.; Tiwari, R.; Chakraborty, S.; Dhama, K. Oxidative stress, prooxidants, and antioxidants: The interplay. *BioMed Res. Int.* **2014**, *2014*, 761264.

8. Bani, D.; Bencini, A. Developing ROS scavenging agents for pharmacological purposes: Recent advances in design of manganese-based complexes with anti-inflammatory and anti-nociceptive activity. *Curr. Med. Chem.* **2012**, *19*, 4431–4444.

9. Kim, H.-R.; Won, S.J.; Fabian, C.; Kang, M.-G.; Szardenings, M.; Shin, M.-G. Mitochondrial DNA aberrations and pathophysiological implications in hematopoietic diseases, chronic inflammatory diseases, and cancers. *Ann. Lab. Med.* **2015**, *35*, 1–14.

10. Salisbury, D.; Bronas, U. Reactive oxygen and nitrogen species: Impact on endothelial dysfunction. *Nurs. Res.* **2015**, *64*, 53–66.

11. Prasad, K.; Dhar, I. Oxidative stress as a mechanism of added sugar-induced cardiovascular disease. *Int. J. Angiol.* **2014**, *23*, 217–226.

12. Hroudová, J.; Singh, N.; Fišar, Z. Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer’s disease. *BioMed Res. Int.* **2014**, *2014*, 175062.

13. Ayala-Peña, S. Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis. *Free Radic. Biol. Med.* **2013**, *62*, 102–110.

14. Karunakaran, U.; Park, K.-G. A systematic review of oxidative stress and safety of antioxidants in diabetes: Focus on islets and their defense. *Diabetes Metab. J.* **2013**, *37*, 106–112.

15. Correia-Melo, C.; Hewitt, G.; Passos, J.F. Telomers, oxidative stress and inflammatory factors: Partners in cellular senescence? *Longev. Healthspan* **2014**, *3*, 1–9.

16. Kumalic, S.I.; Pinter, B. Review of clinical trials on effects of oral antioxidants on basic semen and other parameters in idiopathic oligoasthenoteratozoospermia. *BioMed Res. Int.* **2014**, *2014*, 426951.

17. Powers, S.K. Can antioxidants protect against disuse muscle atrophy? *Sports Med.* **2014**, *44*, S155–S165.

18. Ginter, E.; Simko, V.; Panakova, V. Antioxidants in health and disease. *Bratisl. Lek. Listy* **2014**, *115*, 603–606.

19. Kanchev, V.D.; Kasaikina, O.T. Bio-antioxidants—A chemical base of their antioxidant activity and beneficial effect on human health. *Curr. Med. Chem.* **2013**, *20*, 4784–4805.

20. López-Alarcóna, C.; Denicola, A. Evaluating the antioxidant capacity of natural products: A review on chemical and cellular-based assays. *Anal. Chim. Acta* **2013**, *763*, 1–10.

21. Scartezzini, P.; Speroni, E. Review on some plants of Indian traditional medicine with antioxidant activity. *J. Ethnopharmacol.* **2000**, *71*, 23–43.

22. Sanches-Silva, A.; Costa, D.; Albuquerque, T.G.; Buonocore, G.G.; Ramos, F.; Castilho, M.C.; Machado, A.V.; Costa, H.S. Trends in the use of natural antioxidants in active food packaging: A review. *Food Addit. Contam.* **2014**, *31*, 374–395.

23. Jin, C.; Wu, X.; Zhang, Y. Relationship between antioxidants and acrylamide formation: A review. *Food Res. Int.* **2013**, *51*, 611–620.

24. Liu, Z.-Q. Antioxidants may not always be beneficial to health. *Nutrition* **2014**, *30*, 131–133.
25. Chandra, S.; Khan, S.; Avula, B.; Lata, H.; Yang, M.H.; ElSohly, M.A.; Khan, I.A. Assessment of total phenolic and flavonoid content, antioxidant properties, and yield of aeroponically and conventionally grown leafy vegetables and fruit crops: A comparative study. *Evid.-Based Complement. Altern. Med.* 2014, doi:10.1155/2014/253875.

26. Huguet, V.; Gouy, M.; Normand, P.; Zimpfer, J.F.; Fernandez, M.P. Molecular phylogeny of Myricaceae: A reexamination of host-symbiont specificity. *Mol. Phylogen. Evol.* 2005, 34, 557–568.

27. Yanthan, M.; Misra, A.K. Molecular approach to the classification of medicinally important actinorhizal genus *Myrica*. *Indian J. Biotechnol.* 2013, 12, 133–136.

28. Macdonald, A.D. The morphology and relationships of the Myricaceae. In *Evolution, Systematics, and Fossil History of the Hamamelidae*; Crane, P.R., Blackmore, S., Eds.; Oxford University Press: Oxford, UK, 1989; Volume 2, pp. 147–165.

29. Staples, G.W.; Imada, C.T.; Herbst, D.R. New Hawaiian plant records for 2000. *Bish. Mus. Occas. Pap.* 2002, 68, 3–18.

30. Herbert, J. New combinations and a new species in *Morella* (Myricaceae). *Novon* 2005, 15, 293–295.

31. Gtari, M.; Dawson, J.O. An overview of actinorhizal plants in Africa. *Funct. Plant Biol.* 2011, 38, 653–661.

32. WHO, Traditional Medicine Strategy: 2014–2023. Available online: http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/ (accessed on 10 March 2015).

33. Li, T.S.C. *Taiwanese Native Medicinal Plants: Phytopharmacology and Therapeutic Values*; CRC Press: Florida, FL, USA, 2006; p. 83.

34. Yu, Y.-F.; Lu, Q.; Guo, L.; Mei, R.-Q.; Liang, H.-X.; Luo, D.-Q.; Cheng, Y.-X. Myricananone and myricananadiol: Two new cyclic diarylheptanoids from the roots of *Myrica nana*. *Helv. Chim. Acta* 2007, 90, 1691–1696.

35. Wang, J.-F.; Zhang, C.-L.; Lu, Q.; Yu, Y.-F.; Zhong, H.-M.; Long, C.-L.; Cheng, Y.-X. Three new diarylheptanoids from *Myrica nana*. *Helv. Chim. Acta* 2009, 92, 1594–1599.

36. Lee, S.; Xiao, C.; Pei, S. Ethnobotanical survey of medicinal plants at periodic markets of Honghe Prefecture in Yunnan Province, SW China. *J. Ethnopharmacol.* 2008, 117, 362–377.

37. Schmidt, E.; Lotter, M.; McCleland, W. *Trees and shrubs of Mpumalamga and Kruger National Park*; Jacana Publishers: Johannesburg, South Africa, 2002; p. 70.

38. Moffet, R. *Sesotho Plant and Animal Names, and Plants Used by the Basotho*; Sun Press: Bloemfontein, South Africa, 2010; p. 239, 287.

39. Ashafa, A.O.T. Medicinal potential of *Morella serata* (Lam.) Killick (Myricaceae) root extracts: Biological and pharmacological activities. *BMC Complement. Altern. Med.* 2013, 13, 163–170.

40. Tene, M.; Wabo, K.H.; Kamnaing, P.; Tsopmo, A.; Tane, P.; Ayafora, J.F.; Sterner, O. Diarylheptanoids from *Myrica arborea*. *Phytochemistry* 2000, 54, 975–978.

41. Hoffmann, D.; Hoffmann, F.N. *Medical Herbalism: The Science and Practice of Herbal Medicine*; Inner Traditions/Bear & Company: Vermont, VT, USA, 2003; p. 262, 278, 279, 500, 569.

42. Kefalew, A.; Asfaw, Z.; Kelbessa, E. Ethnobotany of medicinal plants in Ada’a District, East Shewa Zone of Oromia regional state, Ethiopia. *J. Ethnobiol. Ethnomed.* 2015, 11, 1–28.

43. Teklay, A.; Abera, B.; Giday, M. An ethnobotanical study of medicinal plants used in Kilte Awulaelo District, Tigray Region of Ethiopia. *J. Ethnobiol. Ethnomed.* 2013, 9, 1–23.
44. Schlage, C.; Mabula, C.; Mahunnah, R.L.A.; Heinrich, M. Medicinal plants of the Washambaa (Tanzania): Documentation and ethnopharmacological evaluation. *Plant Biol.* **2000**, *2*, 83–92.

45. Sun, C.; Huang, H.; Xu, C.; Li, X.; Chen, K. Biological activities of extracts from Chinese bayberry (*Myrica rubra* Sieb. et Zucc.): A review. *Plant Foods Hum. Nutr.* **2013**, *68*, 97–106.

46. Kirtikar, K.R.; Basu, B.D. *Indian Medicinal Plants*, 2nd ed.; International Book Distributors: New Delhi, India, 1999; Volume 3, p. 1699.

47. Nadkarni’s, K.M. *Indian Materia Medica*, 3rd ed.; Popular Prakshan Pvt Ltd.: Mumbai, India, 2002; Volume 1, p. 871.

48. Laloo, R.C.; Kharlukhi, S.; Jeeva, S.; Mishra, B.P. Status of medicinal plants in the disturbed and the undisturbed sacred forest of Meghalaya, Northeast India: Population structure and regeneration efficacy of some important species. *Curr. Sci.* **2006**, *90*, 225–232.

49. Bich, D.H.; Chung, D.Q.; Chuong, B.X.; Dong, N.T.; Dam, D.T.; Hien, P.V.; Lo, V.N.; Mai, P.D.; Man, P.K.; Nhu, D.T.; et al. *The Medicinal Plants and Animals in Vietnam*; Hanoi Science and Technology Publishing House: Hanoi, Vietnam, 2004; Volume 1, pp. 612–613.

50. Small, E. *North American Cornucopia: Top 100 Indigenous Food Plants*; CRC Press: New York, NY, USA, 2014; p. 669.

51. Panthari, P.; Kharkwal, H.; Kharkwal, H.; Joshi, D.D. *Myrica nagi*: A review on active constituents, biological and therapeutic effects. *Int. J. Pharm. Pharm. Sci.* **2012**, *4*, 38–42.

52. Kumar, A.; Rana, A.C. Pharmacognostic and pharmacological profile of traditional medicinal plant: *Myrica nagi*. *Int. Res. J. Pharm.* **2012**, *3*, 32–37.

53. Vimala, G.; Shoba, F.G. A review on antiulcer activity of few Indian medicinal plants. *Int. J. Microbiol.* **2014**, *2014*, 519590.

54. Tene, M.; Tane, P.; Connolly, J.D. Triterpenoids and diarylheptanoids from *Myrica arborea*. *Biochem. Syst. Ecol.* **2009**, *36*, 872–874.

55. Fang, J.; Paetz, C.; Schneider, B. C-Methylated flavanones and dihydrochalcones from *Myrica gale* seeds. *Biochem. Syst. Ecol.* **2011**, *39*, 68–70.

56. Lv, H.; She, G. Naturally occurring diarylheptanoids. *Nat. Prod. Commun.* **2010**, *5*, 1687–1708.

57. Lv, H.; She, G. Naturally occurring diarylheptanoids—A supplementary version. *Rec. Nat. Prod.* **2012**, *6*, 321–333.

58. Ting, Y.-C.; Ko, H.-H.; Wang, H.-C.; Peng, C.-F.; Chang, H.-S.; Hsieh, P.-C.; Chen, I.-S. Biological evaluation of secondary metabolites from the roots of *Myrica adenophora*. *Phytochemistry* **2014**, *103*, 89–98.

59. Joshi, B.S.; Pelletier, S.W.; Newton, M.G.; Lee, D.; McGaughey, G.B.; Puar, M.S. Extensive 1D, 2D NMR spectra of some [7.0]metacyclophanes and X-ray analysis of (2)-myricanol. *J. Nat. Prod.* **1996**, *59*, 759–764.

60. Nagai, M.; Sakurai, N.; Yumoto, N.; Nagumo, S.; Seo, S. Oleanane acid from *Myrica cerifera*. *Chem. Pharm. Bull.* **2000**, *48*, 1427–1428.

61. Nagai, M.; Dohi, J.; Morihara, M.; Sakurai, N. Diarylheptanoids from *Myrica gale var. tomentosa* and revised structure of porson. *Chem. Pharm. Bull.* **1995**, *43*, 1674–1677.
62. Akazawa, H.; Fujita, Y.; Banno, N.; Watanabe, K.; Kimura, Y.; Manosroi, A.; Manosroi, J.; Akihisa, T. Three new cyclic diarylheptanoids and other phenolic compounds from the bark of *Myrica rubra* and their melanogenesis inhibitory and radical scavenging activities. *J. Oleo. Sci.* **2010**, *59*, 213–221.

63. Wang, J.; Dong, S.; Wang, Y.; Lu, Q.; Zhong, H.; Duc, G.; Zhang, L.; Cheng, Y. Cyclic diarylheptanoids from *Myrica nana* inhibiting nitric oxide release. *Bioorg. Med. Chem.* **2008**, *16*, 8510–8515.

64. Morihara, M.; Sakurai, N.; Inoue, T.; Kawai, K.-I.; Nagai, M. Two novel diarylheptanoid glucosides from *Myrica gale* var. *tormentosa* and absolute structure of plane-chiral galeon. *Chem. Pharm. Bull.* **1997**, *45*, 820–823.

65. Jones, J.R.; Lebar, M.D.; Jinwal, U.K.; Abisambra, J.F.; Koren, J.; III; Blair, L.; O’Leary, J.C.; Davey, Z.; Trotter, J.; Johnson, A.G.; et al. The diarylheptanoid (+)-aR,11S-myricanol and two flavones from bayberry (*Myrica cerifera*) destabilize the microtubule-associated protein Tau. *J. Nat. Prod.* **2011**, *74*, 38–44.

66. Nhiem, N.X.; van Kiem, P.; van Minh, C.; Tai, B.H.; Cuong, N.X.; Thu, V.K.; Anh, H.L.T.; Jo, S.-H.; Jang, H.-D.; Kwon, Y.-I.; et al. A new monoterpenoid glycoside from *Myrica esculenta* and the inhibition of angiotensin I-converting enzyme. *Chem. Pharm. Bull.* **2010**, *58*, 1408–1410.

67. Kim, H.H.; Oh, M.H.; Park, K.J.; Heo, J.H.; Lee, M.W. Anti-inflammatory activity of sulfate-containing phenolic compounds isolated from the leaves of *Myrica rubra*. *Fitoterapia* **2014**, *92*, 188–193.

68. Kim, H.H.; Kim, D.H.; Kim, M.H.; Oh, M.H.; Kim, S.R.; Park, K.J.; Lee, M.W. Flavonoid constituents in the leaves of *Myrica rubra* Sieb. et Zuce. with anti-inflammatory activity. *Arch. Pharm. Res.* **2013**, *36*, 1533–1540.

69. Zhang, Y.-L.; Kong, L.-C.; Yin, C.-P.; Jiang, D.-H.; Jiang, J.-Q.; He, J.; Xiao, W.-X. Extraction optimization by response surface methodology, purification and principal antioxidant metabolites of red pigments extracted from bayberry (*Myrica rubra*) pomace. *LWT Food Sci. Technol.* **2013**, *51*, 343–347.

70. Santos, S.C.; Waterman, P.G. Condensed tannins from *Myrica gale*. *Fitoterapia* **2000**, *71*, 610–612.

71. Tao, J.; Morikawa, T.; Toguchida, I.; Ando, S.; Matsuda, H.; Yoshikawa, M. Inhibitors of nitric oxide production from the bark of *Myrica rubra*: Structures of new biphenyl type diarylheptanoid glycosides and taraxerane type triterpene. *Bioorg. Med. Chem.* **2002**, *10*, 4005–4012.

72. Bamola, A.; Semwal, D.K.; Semwal, S.; Rawat, U. Flavonoid glycosides from *Myrica esculenta* leaves. *J. Indian Chem. Soc.* **2009**, *86*, 535–536.

73. Anthonsen, T.; Lorentzen, G.B.; Malterud, K.E. Porson, a new [7,0]-metacyclophane from *Myrica gale* L. *Acta Chem. Scand. Ser. B* **1975**, *29*, 529–530.

74. Procházková, D.; Boušová, I.; Wilhelmová, N. Antioxidant and prooxidant properties of flavonoids. *Fitoterapia* **2011**, *82*, 513–523.

75. Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. Proceedings of the 3rd International Immunonutrition Workshop, Platja D’Aro, Girona, Spain, 21–24 October 2009; Cambridge University Press: Cambridge, UK, 2010; Volume 69, pp. 273–278.

76. Jatczak, K.; Grynkiewicz, G. Triterpene sapogenins with oleanene skeleton: Chemotypes and biological activities. *Acta Biochim. Pol.* **2014**, *61*, 227–243.
77. Vechia, D.; Gnoatto, L.; Simone, C.B.; Gosmann, G. Oleanane and ursane derivatives and their importance on the discovery of potential antitumour, antiinflammatory and antioxidant drugs. *Quim. Nova.* 2009, 32, 1245–1252.

78. Alam, M.N.; Bristi, N.J.; Rafiquzzaman, M. Review on *in vivo* and *in vitro* methods evaluation of antioxidant activity. *Saudi Pharm. J.* 2013, 21, 143–152.

79. Rubió, L.; Motilva, M.J.; Romero, M.-P. Recent advances in biologically active compounds in herbs and spices: A review of the most effective antioxidant and anti-inflammatory active principles. *Crit. Rev. Food Sci. Nutr.* 2013, 53, 943–953.

80. Tan, J.B.L.; Lim, Y.Y. Critical analysis of current methods for assessing the *in vitro* antioxidant and antibacterial activity of plant extracts. *Food Chem.* 2015, 172, 814–822.

81. Chen, W.; Feng, L.; Shen, Y.; Su, H.; Li, Y.; Zhuang, J.; Zhang, L.; Zheng, X. Myricitrin inhibits acrylamide-mediated cytotoxicity in human Caco-2 cells by preventing oxidative stress. *BioMed Res. Int.* 2013, doi:10.1155/2013/724183.

82. Wang, Y.-H.; Xuan, Z.-H.; Tiana, S.; He, G.-R.; Du, G.-H. Myricitrin attenuates 6-hydroxydopamine-induced mitochondrial damage and apoptosis in PC12 cells via inhibition of mitochondrial oxidation. *J. Funct. Food* 2013, 5, 337–345.

83. Padayatty, S.J.; Katz, A.; Wang, Y.; Eck, P.; Kwon, O.; Lee, J.-H.; Chen, S.; Corpe, C.; Dutta, A.; Dutta, S.K.; Levine, M. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. *J. Am. Coll. Nutr.* 2003, 22, 18–35.

84. Spínola, V.; Llorent-Martínez, E.J.; Gouveia, S.; Castilho, P.C. *Myrica faya*: A new source of antioxidant phytochemicals. *J. Agric. Food Chem.* 2014, 62, 9722–9735.

85. Fu, Y.; Qiao, L.; Cao, Y.; Zhou, X.; Liu, Y.; Ye, X. Structural elucidation and antioxidant activities of proanthocyanidins from Chinese bayberry (*Myrica rubra* Sieb. et Zucc.) leaves. *PLoS ONE* 2014, 9, e96162.

86. Nurieva, R.I.; Chung, Y. Understanding the development and function of T follicular helper cells. *Cell. Mol. Immunol.* 2010, 7, 190–197.

87. Venkatesha, S.H.; Dudics, S.; Acharya, B.; Moudgil, K.D. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. *Int. J. Mol. Sci.* 2015, 16, 887–906.

88. Aktan, F. iNOS-mediated nitric oxide production and its regulation. *Life Sci.* 2004, 75, 639–653.

89. Treuer, A.V.; Gonzalez, D.R. Nitric oxide synthases, S-nitrosylation and cardiovascular health: From molecular mechanisms to therapeutic opportunities. *Mol. Med. Rep.* 2015, 11, 1555–1565.

90. Kalinski, P. Regulation of immune responses by prostaglandin E2. *J. Immunol.* 2012, 188, 21–28.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).